Lee Ainslie’s Corcept Therapeutics CORT Stock Holding History

Lee Ainslie’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,657	Closed	-$404K	–	431
2023 Q1	$404K	Buy	+18,657	New	+$409K	0.01%	344
2020 Q4	–	Sell	-49,246	Closed	-$857K	–	691
2020 Q3	$857K	Sell	49,246 -5,618	-10%	-$89.5K	0.02%	319
2020 Q2	$923K	Buy	+54,864	New	+$771K	0.02%	336

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Lee Ainslie's CORT Position: Q2 2023 in Review

Lee Ainslie sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 18,657 shares — an estimated $404K sold.

Lee Ainslie first reported a position in CORT in Q2 2020 and held it in 3 quarters. The position peaked at $923K in Q2 2020. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

Lee Ainslie reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
Lee Ainslie sold 18,657 Corcept Therapeutics shares in Q2 2023, an estimated $404K.
Lee Ainslie first reported a position in Corcept Therapeutics in Q2 2020 and held it in 3 quarters.
Lee Ainslie's Corcept Therapeutics position peaked at $923K in Q2 2020.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Maverick Capital's 13F filing for Q2 2023, filed 14 Aug 2023.